Orion Infusion Ltd

Orion Infusion Ltd maintains a debt-to-equity ratio of 0.98, indicating a balanced capital structure with moderate leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.94, suggesting limited short-term liquidity cushion. Free cash flow of $24.7 million supports operational flexibility, though the absence of cash and equivalents highlights a reliance on cash flow generation rather than liquidity reserves. Profitability metrics show a return on equity of 10.74% and a return on assets of 4.13%, both below the median for the Pharmaceuticals industry. The company's operating margin of 12.97% (calculated from operating income of $86.3 million on revenue of $665 million) is also below the industry median, indicating room for improvement in cost control or pricing power. Geographically, Orion Infusion's revenue is concentrated in a single market, with no disclosed diversification across regions or product lines. This concentration increases exposure to local regulatory, economic, and competitive shifts. Segment-wise, the company operates as a single business unit, with no material diversification across therapeutic areas or product categories. Outlook for the current fiscal year shows a projected revenue increase of 12.5% year-over-year, driven by new product launches and expanded distribution. For the next fiscal year, revenue is expected to grow by 8.2%, reflecting continued market penetration and stable demand for IV therapies. Historical revenue growth has averaged 9.3% annually over the past three years. Risk factors include a medium liquidity risk due to the absence of cash and equivalents and a current ratio below 1. The company has a low dilution risk, with no near-term pressure from share issuance or convertible debt. However, the risk assessment flags a negative net cash position after subtracting total debt, which could constrain flexibility in capital allocation. Recent events include the filing of a 10-K annual report disclosing the company's financial position and risk factors, as well as a Q4 earnings call transcript highlighting progress in product development and market expansion.